Excited to be part of this team focused on the molecular pathogenesis of pediatric lupus nephritis. bit.ly/GTSA23. Lead by the brilliant Elena Hsieh.

We are pleased to announce the recipients of this year’s Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that aim to improve therapies for people with #SLE. Learn more: bit.ly/LRA-LMTA #lupus #lupusresearch

Excited to announce new funding from Lupus Research, in a collaborative project with Brad H Rovin and Ana Malvar (Buenos Aires, Argentina). Lupus Mechanisms and Targets Award (LTMA) focused on molecular predictors of treatment response in lupus nephritis. bit.ly/LRA-LMTA

In Journal of Experimental Medicine, Aaron Liu, Mridu Acharya, Shaun Jackson et al. show that loss-of-function mutations in NADPH oxidase complex promote SLE by modulating B cell Toll-like receptor signaling. hubs.la/Q02ncT_k0 Seattle Children's @UWPediatrics #Autoimmunity #lupus

Some exciting news from Seattle Children's. Looking forward to working with Seattle Children's Therapeutics (SCTx) to lead the first US clinical trial of anti-CD19 CAR T cells in childhood-onset SLE. Seattle Children's

NEWS—CAR T-cell therapy for #SLE in children thelancet.com/journals/lanrh… Seattle Children's

We are excited to share that Seattle Children’s is now enrolling for the first chimeric antigen receptor (CAR) T-cell clinical trial in the U.S. for children with systemic lupus erythematosus (SLE). The clinical trial, known as REACT-01 is led by Seattle Children's Therapeutics (SCTx), a novel